Cardiorenal Syndrome Medical Services in China

Cardiorenal syndrome (CRS) is a pathophysiologic disorder in which acute or chronic dysfunction of the heart or kidneys induces acute or chronic dysfunction of the other organ. It is not a single disease but a spectrum of interrelated conditions classified into five subtypes (Type 1–5) based on the primary insult (cardiac vs. renal), temporal sequence (acute vs. chronic), and direction of organ crosstalk. Type 1 (acute CRS) involves abrupt worsening of cardiac function leading to acute kidney injury; Type 2 (chronic CRS) reflects chronic heart failure driving progressive chronic kidney disease; Type 3 (acute renocardiac syndrome) arises from acute kidney injury triggering acute cardiac events; Type 4 (chronic renocardiac syndrome) denotes chronic kidney disease contributing to decreased cardiac function and increased cardiovascular mortality; and Type 5 (secondary CRS) refers to systemic disorders (e.g., sepsis, diabetes, autoimmune vasculitis) causing simultaneous cardiac and renal dysfunction. Pathogenesis centers on neurohormonal activation (RAAS, SNS), inflammatory cytokine release, oxidative stress, endothelial dysfunction, hemodynamic imbalance (reduced renal perfusion, venous congestion), and maladaptive cardiorenal reflexes. Epidemiologically, CRS affects an estimated 25–40% of hospitalized heart failure patients and up to 60% of those with advanced chronic kidney disease; prevalence rises sharply with age, comorbid diabetes, hypertension, and prior cardiovascular events. Risk factors include advanced age (>65 years), diabetes mellitus, arterial hypertension, coronary artery disease, atrial fibrillation, obesity, chronic kidney disease (eGFR <60 mL/min/1.73m²), proteinuria, and recurrent hospitalizations for decompensated heart failure. CRS profoundly impairs quality of life: patients experience debilitating fatigue, dyspnea, orthopnea, peripheral edema, reduced exercise tolerance, sleep disturbances, anxiety, depression, and social isolation. Frequent hospital readmissions, polypharmacy burden, dietary restrictions (low-sodium, low-potassium, fluid-limited regimens), and progressive functional decline severely limit independence and daily activities. Early diagnosis remains challenging due to overlapping symptoms (e.g., weight gain, oliguria, elevated BNP, rising creatinine) and lack of standardized biomarkers beyond serum creatinine, cystatin C, NT-proBNP, and novel markers like NGAL or TIMP-2•IGFBP7 under investigation. Multidisciplinary management—integrating nephrology, cardiology, and palliative care—is essential to mitigate progression, optimize volume status, preserve residual renal function, and improve survival.

Cardiorenal syndrome (CRS) is a pathophysiologic disorder characterized by bidirectional dysfunction between the heart and kidneys, where acute or chronic injury to one organ induces acute or chronic dysfunction in the other. Classified into five subtypes (Type 1–5) based on temporal sequence and chronicity of cardiac and renal involvement, CRS presents a complex clinical challenge requiring integrated, multidisciplinary management. In nephrology practice, early recognition—particularly of Type 1 (acute cardiorenal), Type 2 (chronic cardiorenal), and Type 3 (acute renocardiac)—is critical to mitigate irreversible end-organ damage and reduce mortality.

Conservative treatment forms the cornerstone of CRS management and must be initiated promptly upon diagnosis. Fluid balance optimization is paramount: daily intake and output monitoring, strict fluid restriction (typically 1.5–2.0 L/day in volume-overloaded patients), and serial assessment of jugular venous pressure, lung auscultation, and peripheral edema guide decongestive strategies. Nutritional support emphasizes low-sodium (<2 g/day), low-potassium (if hyperkalemic), and moderate-protein (0.8–1.0 g/kg/day) diets to reduce cardiac afterload, prevent arrhythmias, and minimize nitrogenous waste accumulation. Non-pharmacologic interventions include supervised exercise rehabilitation for stable chronic CRS patients, smoking cessation, alcohol abstinence, and weight monitoring (>2 kg weight gain over 3 days warrants clinical reassessment). Continuous noninvasive hemodynamic monitoring (e.g., bioimpedance cardiography) and remote telemonitoring of vital signs and symptoms are increasingly employed in outpatient settings to detect early decompensation.

Pharmacotherapy requires careful risk–benefit stratification due to altered pharmacokinetics and heightened susceptibility to adverse effects in CRS. Diuretics remain first-line for volume overload; loop diuretics (e.g., intravenous furosemide or bumetanide) are preferred, often administered as continuous infusions or in combination with thiazide-like agents (e.g., metolazone) for synergistic natriuresis—though electrolyte monitoring (Na⁺, K⁺, Mg²⁺, Cr) and renal function surveillance are mandatory. Renin–angiotensin–aldosterone system inhibitors (RAASi), including ACE inhibitors, ARBs, or MRAs (e.g., spironolactone), improve long-term outcomes in chronic CRS but require cautious up-titration with serum potassium <5.0 mmol/L and eGFR >30 mL/min/1.73m². SGLT2 inhibitors (e.g., dapagliflozin, empagliflozin) have emerged as disease-modifying agents with robust cardio-renal protective effects demonstrated in trials such as DAPA-HF and EMPEROR-Reduced; they reduce hospitalization for heart failure and slow eGFR decline independent of glycemic control. Beta-blockers (e.g., carvedilol, bisoprolol) are indicated in systolic heart failure but must be withheld during acute decompensation. Vasodilators (e.g., nitroglycerin, nesiritide) may be used short-term in acute pulmonary edema, while inotropes (e.g., dobutamine) are reserved for cardiogenic shock with severe hypoperfusion. Anticoagulation is individualized based on atrial fibrillation burden and bleeding risk; direct oral anticoagulants (DOACs) are preferred over warfarin when renal function permits (CrCl >30 mL/min).

Surgical and procedural interventions are adjunctive and reserved for refractory or advanced cases. Ultrafiltration (UF) is considered when diuretic resistance persists despite optimal medical therapy and carries lower risk of electrolyte shifts than high-dose diuretics—but requires vascular access and close hemodynamic monitoring to avoid hypotension-induced renal ischemia. Percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is indicated for significant ischemic heart disease contributing to CRS. Cardiac resynchronization therapy (CRT) improves ventricular synchrony and reduces mitral regurgitation in selected patients with dyssynchrony and reduced ejection fraction. Left ventricular assist devices (LVADs) serve as bridge-to-transplant or destination therapy in end-stage heart failure complicated by reversible renal impairment; post-LVAD renal recovery correlates strongly with pre-implant renal reserve. Kidney transplantation in CRS patients remains highly selective—requiring stable cardiac function (LVEF ≥40%, absence of uncontrolled arrhythmias or severe pulmonary hypertension), thorough preoperative cardiopulmonary evaluation, and multidisciplinary consensus.

Treatment advantages in China reflect rapid integration of evidence-based protocols with innovative infrastructure and policy support. The National Health Commission’s Chronic Disease Management Program mandates standardized CRS screening in tier-2 and tier-3 hospitals, enabling earlier detection via centralized electronic health records linking cardiology and nephrology departments. China leads globally in real-world adoption of AI-powered predictive analytics (e.g., deep learning models using ECG, BNP, and creatinine trajectories) to forecast CRS decompensation 48–72 hours in advance. High-volume centers such as Peking University First Hospital and Shanghai Renji Hospital offer dedicated CRS clinics with co-located nephrologists, cardiologists, and specialized nurses, reducing diagnostic delays and improving adherence. Domestic development of cost-effective biosimilars (e.g., recombinant BNP assays, generic SGLT2 inhibitors) enhances accessibility, while national reimbursement policies now cover SGLT2 inhibitors and home UF devices under the Basic Medical Insurance scheme. Furthermore, China’s robust traditional medicine research infrastructure supports rigorous clinical trials evaluating adjunctive therapies like Huangqi injection (Astragalus membranaceus), which has demonstrated anti-fibrotic and endothelial-protective effects in randomized controlled studies—though integration remains complementary and evidence-guided.

Recovery and long-term prognosis depend heavily on patient engagement and structured follow-up. Patients should attend scheduled nephrology–cardiology joint clinics every 1–3 months, with quarterly NT-proBNP, cystatin C–based eGFR, and echocardiographic assessments. Home blood pressure and weight logs must be reviewed at each visit; self-reported dyspnea (using validated scales like the MLHFQ) aids functional assessment. Vaccination against influenza and pneumococcus is strongly recommended. Psychosocial support—including cognitive behavioral therapy for anxiety/depression and peer-led support groups—is integral, given the high prevalence of depression in CRS (up to 35%). Smoking cessation counseling and structured dietary education by certified renal dietitians significantly improve outcomes. Finally, advance care planning discussions—including goals of care, preferences for ICU admission, and dialysis initiation—should occur early in progressive CRS to align treatment with patient values and avoid non-beneficial interventions.